{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:32:47Z","timestamp":1777883567761,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"NIH NIDA","award":["5R01DA033391-05"],"award-info":[{"award-number":["5R01DA033391-05"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We assess adverse events (AEs) following medication initiation for adolescents and young adults with opioid use disorder (OUD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a secondary analysis of a clinical trial of long-acting injectable naltrexone (LAI-naltrexone) among youth with OUD aged 15 to 21\u2009years. Participants were recruited from residential treatment and placed into 1 of 3 treatment groups based on medication receipt at time of discharge (no medication, sublingual buprenorphine-naloxone [buprenorphine], or LAI-naltrexone). Frequencies and percentages of AEs by body system were compared by medication group at the 1-month follow-up visit. Logistic regression was used to compare groups on their likelihood of reporting an AE, overall and excluding injection site reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 199 participants, 71 (36%) received no medication, 59 (30%) buprenorphine, and 69 (35%) LAI-naltrexone at discharge. Participants who received LAI-naltrexone experienced more AEs, primarily due to injection site reactions (62%, accounting for 43% of all AEs among participants who received LAI-naltrexone). There were 6 reports of nonlethal overdose, 5 in the no medication, 1 in the buprenorphine, and none in the LAI-naltrexone group. Participants receiving LAI-naltrexone were more likely to report an AE compared to the other groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.04), but this difference was no longer significant when excluding injection site reactions (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.82).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Excluding injection site reactions, there were no significant differences in the likelihood of reporting an AE 1\u2009month after receiving LAI-NTX, buprenorphine, and no medications. LAI-naltrexone should be among the medications offered for the treatment of OUD in youth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241275738","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:13:49Z","timestamp":1743743629000},"page":"72-77","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Events at 1\u2009Month Following Medication Initiation for Opioid Use Disorder Among Adolescents and Young Adults"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-2942","authenticated-orcid":false,"given":"Mishka","family":"Terplan","sequence":"first","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin E.","family":"O\u2019Grady","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Maryland, College Park, College Park, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura B.","family":"Monico","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Gryczynski","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.","family":"Fishman","sequence":"additional","affiliation":[{"name":"Mountain Manor Treatment Center, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon Gwin","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1893"},{"key":"e_1_3_3_3_2","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2019","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health. HHS Pub No. PEP19 5068, NSDUH Series H-54. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304673"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.12.023"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3821"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2143"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.04.002"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2020.07.038"},{"key":"e_1_3_3_10_2","volume-title":"Extended Release Naltrexone Research With Adolescents and Young Adults","author":"Mitchell S","year":"2018","unstructured":"Mitchell S, Schwartz R., Fishman M., Zarkin G., Dunlap L. Extended Release Naltrexone Research With Adolescents and Young Adults. NIDA\/SAMHSA Panel; 2018."},{"key":"e_1_3_3_11_2","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2019.80.403"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108407"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0110-x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108422"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0705-8"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14180"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2019.1605372"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241275738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241275738","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241275738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:21Z","timestamp":1777600221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241275738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/29767342241275738"],"URL":"https:\/\/doi.org\/10.1177\/29767342241275738","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}